Safety of an IV formulation of carbamazepine

Jeannine M. Conway, James R. White, Angela K. Birnbaum, R. Eugene Ramsay, Page B. Pennell, John O. Rarick, Luna Musib, Ilo E. Leppik, James C. Cloyd

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100 mg of study drug as replacement for 100 mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.

Original languageEnglish (US)
Pages (from-to)242-244
Number of pages3
JournalEpilepsy Research
Issue number2-3
StatePublished - Apr 2009

Bibliographical note

Funding Information:
This work was supported by NIH-NINDS P50-NS16308, NCRR M01-RR00400, M01-RR00039, and M01 RR16587.


  • Adults
  • Carbamazepine
  • Elderly
  • Epilepsy
  • Intravenous


Dive into the research topics of 'Safety of an IV formulation of carbamazepine'. Together they form a unique fingerprint.

Cite this